Jump Financial, LLC Kodiak Sciences Inc. Transaction History

Jump Financial, LLC

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	SELL	$2.2 - $3.25 $42,680 - $63,050	-19,400 Closed	0 $0
Q2 2024 Aug 14, 2024	BUY	$2.29 - $4.48 $44,426 - $86,912	19,400 New	19,400 $45,000
Q1 2023 Oct 21, 2024	BUY	$4.81 - $8.88 $234,246 - $432,456	48,700 Added 251.03%	68,100 $422,000
Q1 2023 May 03, 2023	BUY	$4.81 - $8.88 $176,084 - $325,079	36,608 Added 116.25%	68,100 $422,000
Q4 2022 Feb 13, 2023	SELL	$6.52 - $8.05 $80,750 - $99,699	-12,385 Reduced 28.23%	31,492 $225,000
Q3 2022 Nov 07, 2022	SELL	$7.57 - $12.5 $45,919 - $75,825	-6,066 Reduced 12.15%	43,877 $340,000
Q2 2022 Aug 09, 2022	SELL	$5.04 - $9.48 $18,128 - $34,099	-3,597 Reduced 6.72%	49,943 $381,000
Q1 2022 May 12, 2022	BUY	$7.09 - $89.45 $379,598 - $4.79 Million	53,540 New	53,540 $413,000
Q3 2021 Nov 12, 2021	SELL	$81.97 - $106.94 $221,974 - $289,593	-2,708 Closed	0 $0
Q2 2021 Aug 13, 2021	BUY	$77.2 - $126.54 $209,057 - $342,670	2,708 New	2,708 $252,000
Q4 2020 Feb 12, 2021	SELL	$60.78 - $154.03 $619,956 - $1.57 Million	-10,200 Closed	0 $0
Q3 2020 Nov 13, 2020	BUY	$45.05 - $59.27 $459,510 - $604,554	10,200 New	10,200 $604,000

39M

6.5K

5.8K

Ticker KOD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 52,040,200
Market Cap $288M
Description
Kodiak Sciences Inc., a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is KSI-301, an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as we...

Get notified when there are updates to the investment portfolio of Jump Financial, LLC, based on Form 13F filings with the SEC.

Stay updated on Jump Financial, LLC with notifications on news.